FOXO4-DRI UK Research Peptide for Advanced Senolytic Applications
FOXO4-DRI UK research peptide is one of the most extensively studied senolytic compounds within cellular-senescence, p53-signalling and ageing-biology research literature. At Lavish Peptides, we supply premium-quality FOXO4-DRI peptide products for laboratory and in vitro research applications throughout the United Kingdom and Europe, including London, Manchester, Birmingham, Liverpool, Leeds, Glasgow, Edinburgh, Dublin, Paris, Berlin, Amsterdam, Madrid, Milan and Rome.
FOXO4-DRI, also known as Forkhead Box O4 D-Retro-Inverso peptide, is a synthetic cell-penetrating senolytic peptide engineered to selectively induce apoptosis in senescent cells by disrupting the FOXO4–p53 protein interaction. Scientific investigations have identified FOXO4-DRI as one of the defining peptide tools within the modern senolytic research field because of its highly selective mechanism targeting FOXO4-high senescent cells while leaving non-senescent cells comparatively unaffected.
Research literature has characterised FOXO4-DRI as a D-retro-inverso peptide in which the amino acid sequence of the FOXO4 p53-binding region is reversed and synthesised entirely from D-amino acids. Published investigations documented that this structural design preserves the side-chain topology of the native FOXO4 interaction surface while dramatically improving proteolytic stability and intracellular persistence relative to equivalent L-amino-acid peptide systems.
Scientific investigations have additionally demonstrated that FOXO4-DRI binds directly to the p53 transactivation domain 2 (TAD2), competitively displacing FOXO4 and triggering p53 nuclear exclusion, mitochondrial translocation, BAX activation and caspase-3-mediated apoptosis selectively within senescent cells. Research literature further documented that FOXO4 expression is substantially elevated in senescent cells compared with most non-senescent adult tissues, providing the mechanistic basis for FOXO4-DRI’s selectivity profile.
Each FOXO4-DRI UK peptide vial supplied by Lavish Peptides is produced according to strict laboratory-focused standards and supplied as a lyophilised powder in sealed laboratory-grade vials designed to support product integrity during transport and storage. Every batch undergoes third-party HPLC analytical verification procedures to support high purity and consistency expectations for laboratory and analytical applications.
Researchers throughout England, Scotland, Ireland, Germany, France, Spain, Italy, the Netherlands, Belgium, Austria, Portugal and wider Europe increasingly seek trusted peptide suppliers capable of combining premium sourcing standards with dependable fulfilment procedures and discreet shipping services. Lavish Peptides continues supporting laboratories and senescence researchers throughout the UK and Europe with premium peptide compounds and professional customer support.
Researchers interested in exploring additional premium peptide compounds can also browse our full peptide collection through the Lavish Peptides online catalogue.
Premium FOXO4-DRI UK Laboratory Standards
At Lavish Peptides, quality assurance remains central to every peptide product supplied throughout the UK and Europe. Every FOXO4-DRI UK batch undergoes third-party HPLC verification procedures designed to support analytical purity and consistency expectations for laboratory and in vitro research use.
The peptide is supplied within sealed amber laboratory vials intended to help minimise unnecessary environmental exposure during transport and storage. Orders are processed using discreet packaging and secure fulfilment procedures for customers throughout London, Manchester, Birmingham, Glasgow, Edinburgh, Paris, Berlin, Amsterdam, Madrid and Milan.
Researchers throughout England, Ireland, France, Germany, Spain and Italy continue seeking reliable peptide suppliers capable of delivering premium-quality senolytic research compounds with dependable shipping and transparent fulfilment standards. Lavish Peptides remains committed to supporting peptide researchers throughout Europe with premium peptide products and responsive customer support.
As cellular-senescence and longevity-pathway research continue expanding internationally, laboratories increasingly prioritise suppliers with strong quality-control standards and reliable fulfilment operations. Our objective is to provide premium peptide sourcing for research-focused customers across the UK and European peptide market.
Scientific Interest in FOXO4-DRI UK Research
FOXO4-DRI UK research continues receiving substantial attention within peptide-science literature and laboratory investigations involving senescent-cell elimination, apoptosis signalling and ageing-pathway analysis.
Research involving FOXO4-DRI has discussed:
- FOXO4–p53 protein interaction disruption
- p53 TAD2 competitive binding studies
- Senescent-cell selective apoptosis
- BAX/BCL-2/caspase-3 signalling pathways
- SASP suppression and inflammatory signalling
- Vascular-ageing and endothelial-senescence research
- Chondrocyte and cartilage-regeneration studies
- Comparative senolytic pathway investigations
Published scientific investigations have demonstrated that FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting FOXO4-mediated nuclear retention of p53. Research literature additionally documented that released phosphorylated p53 translocates to mitochondria, activating BAX signalling and downstream caspase-3 cleavage associated with intrinsic apoptosis.
Scientific literature has additionally confirmed that FOXO4-DRI displays substantial selectivity for senescent cells because FOXO4 expression is significantly upregulated in senescent populations but remains comparatively low in most non-senescent adult tissues. Published studies therefore identified FOXO4-DRI as one of the most selective peptide-based senolytic systems currently characterised.
Several investigations have examined FOXO4-DRI within ageing and tissue-function research. A landmark study published in Cell demonstrated that FOXO4-DRI treatment improved physical fitness, fur density, liver function and renal function in naturally aged mouse models following selective senescent-cell elimination.
Research literature has further explored FOXO4-DRI within vascular-ageing and endothelial-cell senescence investigations. Published studies demonstrated suppression of aortic ageing markers, improved endothelial-cell function and activation of p53/BCL-2/caspase-3 apoptosis pathways selectively within senescent endothelial populations.
Scientific investigations additionally documented important applications for FOXO4-DRI within Leydig-cell senescence, keloid fibroblast biology and chondrocyte-regeneration studies. Research also explored structural NMR analyses of the FOXO4-DRI/p53 TAD2 complex and comparative evaluations involving Dasatinib + Quercetin, navitoclax and other senolytic systems.
Research institutions and peptide laboratories throughout London, Dublin, Berlin, Stockholm, Copenhagen, Vienna and Amsterdam continue exploring advanced senolytic compounds within controlled scientific environments. Interest in apoptosis-selective peptides and cellular-senescence pathway compounds continues increasing throughout the UK and European scientific sector as laboratories seek advanced molecules for receptor and pathway analysis.
For researchers seeking additional peptide information and fulfilment experiences, our customer testimonials provide insight into the standards and customer experience offered by Lavish Peptides throughout the UK and Europe.
UK and European Peptide Delivery
Lavish Peptides provides fast and discreet shipping for FOXO4-DRI UK peptide products throughout England, Scotland, Wales, Northern Ireland, Ireland, France, Germany, Spain, Italy, Belgium, Austria, Portugal, Sweden, Denmark, Poland and the Netherlands.
Researchers throughout London, Manchester, Liverpool, Birmingham, Leeds, Glasgow, Edinburgh, Paris, Berlin, Amsterdam, Madrid, Milan and Rome continue relying on secure peptide fulfilment services and dependable delivery standards when sourcing laboratory compounds online.
Every FOXO4-DRI UK order is packaged carefully to support customer privacy and maintain product integrity throughout transportation. Our fulfilment procedures are designed to support laboratories and research-focused customers seeking efficient peptide sourcing across Europe.
Researchers interested in additional premium peptide compounds may also wish to explore our Epithalon peptide product available through the Lavish Peptides research catalogue.
Storage and Handling Recommendations
FOXO4-DRI UK research peptides should be handled according to appropriate laboratory handling standards and storage procedures. Researchers commonly store lyophilised peptide compounds in cool, dry environments away from direct sunlight and unnecessary temperature fluctuations.
Maintaining controlled storage conditions may help preserve peptide integrity during laboratory and analytical applications. Proper laboratory procedures should always be followed during preparation, handling and peptide research activities.
Lavish Peptides recommends reviewing internal laboratory protocols and safe handling standards before working with peptide compounds within laboratory environments.
Why Researchers Choose Lavish Peptides
Lavish Peptides continues establishing itself as a trusted supplier within the UK and European peptide market by focusing on premium sourcing, third-party verification and professional fulfilment standards.
Researchers choose Lavish Peptides for:
- Premium research-grade peptide sourcing
- Third-party HPLC-verified purity
- Fast UK dispatch
- Discreet packaging
- Reliable EU shipping
- Secure checkout experience
- Responsive customer support
- Laboratory-focused fulfilment standards
Our objective is to provide premium peptide compounds for laboratory and analytical use throughout Europe while maintaining dependable customer support and strict quality expectations.
For laboratory and in vitro research use only. Not for human consumption. Not a medicine.
Reviews
There are no reviews yet.